BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Bristol Myers Squibb’s Dividend Appeal Amid Patent Cliffs
Bristol Myers Squibb’s Dividend Appeal Amid Patent Cliffs
21
3
BTCCSquare news:
Bristol Myers Squibb (BMY) presents a paradox for income investors. The pharmaceutical giant offers a towering 5.5% dividend yield—nearly 5x the S&P 500 average—despite 25 consecutive years of payout growth. This anomaly stems from market skepticism around patent expirations for blockbusters like Revlimid and Eliquis, which together accounted for nearly half of 2021 revenue.
The bear case overlooks the company's emerging growth drivers. Seven recently launched therapies posted double-digit sales increases last quarter, with cancer treatment Breyanzi more than doubling revenue. FDA-approved schizophrenia drug Cobenfy represents another potential catalyst, though its commercial trajectory remains unproven.
By:
